scholarly journals Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

2016 ◽  
Vol 115 (11) ◽  
pp. 1313-1320 ◽  
Author(s):  
Jonathan A Ledermann ◽  
Philipp Harter ◽  
Charlie Gourley ◽  
Michael Friedlander ◽  
Ignace Vergote ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Serous Ovarian Cancer ◽  
Platinum Sensitive

scholarly journals Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)

2020 ◽  
Vol 30 (4) ◽  
pp. 509-514
Author(s):  
Irena Rohr ◽  
Sara Alavi ◽  
Rolf Richter ◽  
Maren Keller ◽  
Radoslav Chekerov ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Adverse Effects ◽  
Maintenance Therapy ◽  
Oral Administration ◽  
Epithelial Ovarian Cancer ◽  
Recurrent Disease ◽  
The Internet ◽  
Primary Epithelial Ovarian Cancer

BackgroundMaintenance therapy induces remission and prolongs disease free interval in primary and recurrent ovarian disease. For the treatment decision making process, aspects of quality of life and patients′ preferences are crucial, despite the fact that scientific data are lacking. Therefore, we conducted this European-wide study in patients with ovarian cancer.MethodsA 25 item questionnaire was provided to ovarian cancer patients via the internet or as a paper version in 10 European countries (Austria, Belgium, France, Germany, Italy, Romania, Slovenia, Finland, Turkey, and Spain). Data recorded were demographics, tumor stage, therapy after firstline and recurrent disease, preferences for administration, and expectations concerning maintenance therapy.ResultsOverall, 1954 patients participated from September 2013 to March 2016; 42% had recurrent disease. Most patients (98%) with primary epithelial ovarian cancer underwent surgery followed by chemotherapy (91%). Almost one-third of participants (29%) were receiving maintenance therapy whereas 45% had only heard of it. For 70% of patients with primary epithelial ovarian cancer, they heard about maintenance therapy from their doctor, 10% heard about maintenance therapy from other patients, and 8% from the internet. The main source of information about maintenance therapy in patients with epithelial ovarian cancer relapse was from the treating physician (72%), from other patients (8%), and from the internet (7%). For patients undergoing maintenance therapy, the four most disturbing adverse effects were polyneuropathy (37%), nausea (36%), hair loss (34%), and vomiting (34%). The main objective of maintenance treatment, as perceived by patients, was to increase the chances of cure (73%), improvement in quality of life (47%), and delay in tumor growth (37%). Many patients were willing to undergo maintenance therapy until tumor progression (38%) and 39% would prefer oral administration. No significant differences were detected in the cross country subanalysis regarding expectations of maintenance therapy and patients with primary or relapsed ovarian cancer.ConclusionPatients with ovarian cancer were willing to accept maintenance therapy of prolonged duration and preferred oral administration. There is still a gap between the efficacy of maintenance therapy and patient expectations. Patients need more information on the adverse effects and treatment goals of maintenance therapy to avoid misunderstandings.

scholarly journals PCN108 Quality of Life and Patient Preferences in Platinum Sensitive Ovarian Cancer

2012 ◽  
Vol 15 (7) ◽  
pp. A429
Author(s):  
N. Kiss ◽  
M. Sidhu ◽  
V. Tongbram ◽  
L. Harris
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Patient Preferences ◽  
Platinum Sensitive

Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

2008 ◽  
Vol 26 (19) ◽  
pp. 3176-3182 ◽  
Author(s):  
Jalid Sehouli ◽  
Dirk Stengel ◽  
Guelten Oskay-Oezcelik ◽  
Alain G. Zeimet ◽  
Harald Sommer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Overall Survival ◽  
Objective Response ◽  
Progression Free Survival ◽  
Recurrent Ovarian Cancer ◽  
Free Survival ◽  
Platinum Sensitive ◽  
Platinum Refractory

PurposeThe management of recurrent ovarian cancer remains controversial. Single-agent topotecan is an established treatment option, and preliminary evidence suggests improved tumor control by combining topotecan with etoposide or gemcitabine.Patients and MethodsWomen with relapsed ovarian cancer after primary surgery and platinum-based chemotherapy were randomly assigned to topotecan monotherapy 1.25 mg/m2/d, topotecan 1.0 mg/m2plus oral etoposide 50 mg/d, or topotecan 0.5 mg/m2/d plus gemcitabine 800 mg/m2on day 1 and 600 mg/m2on day 8 every 3 weeks. Patients were stratified for platinum-refractory and platinum-sensitive disease according to a recurrence-free interval of less or more than 12 months, respectively. The primary end point was overall survival. Secondary end points included progression-free survival, objective response rates, toxicity, and quality of life (as measured by the European Organisation for Research and Treatment of Cancer [EORTC] 30-item Quality-of-Life Questionnaire).ResultsThe trial enrolled 502 patients with a mean age of 60.5 years (± 10.2 years), 208 of whom were platinum resistant. Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344). Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months). The median progression-free survival was 7.0, 7.8, and 6.3 months, respectively. Objective response rates were 27.8%, 36.1%, and 31.6%, respectively. Patients under combined treatment were at higher risk of severe thrombocytopenia.ConclusionNonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.

Quality of Life and Treatment Response Among Women With Platinum-Resistant Versus Platinum-Sensitive Ovarian Cancer Treated for Progression

2014 ◽  
Vol 69 (5) ◽  
pp. 257-259
Author(s):  
Vanessa L. Beesley ◽  
Adele C. Green ◽  
David K. Wyld ◽  
Peter OʼRourke ◽  
Leesa F. Wockner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Treatment Response ◽  
Platinum Sensitive ◽  
Platinum Resistant

Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer

2014 ◽  
Vol 69 (10) ◽  
pp. 594-596 ◽  
Author(s):  
Jonathan Ledermann ◽  
Philipp Harter ◽  
Charlie Gourley ◽  
Michael Friedlander ◽  
Ignace Vergote ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Serous Ovarian Cancer ◽  
Platinum Sensitive
Sign in / Sign up

Export Citation Format

Share Document